Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar with Temozolomide and Irinotecan for Recurrent Gliomas
NCT04267978Phase 2Recruiting
- Sponsor
- Beijing Sanbo Brain Hospital
- Start
- Feb 2020
- Primary completion
- Dec 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of endostar in glioblastoma (GBM), glioma, sponsored by Beijing Sanbo Brain Hospital. Started Feb 2020; status: recruiting.
02
Drugs
endostar
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NCT04267978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267978.